LGBT Cancer Project

Liver Cancer Clinical Trials

A listing of Liver Cancer medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

 

Alabama

NEW

Research Center
Additional Locations Alabama

Phase II/III Randomized study of Sorafenib plus Doxorubicin versus sorafenib in patients with advanced HCC

Alaska

NEW

Research Center
Additional Locations Alaska

Phase II/III Randomized study of Sorafenib plus Doxorubicin versus sorafenib in patients with advanced HCC

Arizona

NEW

Research Center
Additional Locations Arizona

Phase II/III Randomized study of Sorafenib plus Doxorubicin versus sorafenib in patients with advanced HCC

NEW

Research Center
Phoenix Arizona

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

NEW

Research Center
Tucson Arizona

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

California

NEW

Research Center
Additional Locations California

A Phase III randomized, placebo-controlled, double-blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus Placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC)

NEW

Research Center
Additional Locations California

Phase II/III Randomized study of Sorafenib plus Doxorubicin versus sorafenib in patients with advanced HCC

NEW

Research Center
Orange California

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

NEW

Research Center
San Francisco California

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

UPDATED

Los Agneles California 90033

A Phase 1 clinical study for patients with Neoplasms, Advanced Solid Tumors

UPDATED

Los Angeles California 90024

A Phase 1 clinical study for patients with Neoplasms, Advanced Solid Tumors

UPDATED

Los Angeles California 90033

A Phase 1 clinical study for patients with Neoplasms, Advanced Solid Tumors

UPDATED

Los Angeles California 90095

A Phase 1 clinical study for patients with Neoplasms, Advanced Solid Tumors

UPDATED

Los Angeles California 90025

A Phase 1 clinical study for patients with Neoplasms, Advanced Solid Tumors

UPDATED

Los Angeles California 90095-6984

A Phase 1 clinical study for patients with Neoplasms, Advanced Solid Tumors

UPDATED

Los Angeles California 90033

A Phase 1 clinical study for patients with Neoplasms, Advanced Solid Tumors

UPDATED

Los Angeles California 90095

A Phase 1 clinical study for patients with Neoplasms, Advanced Solid Tumors

UPDATED

Newport Beach California 92663

A Phase 1 clinical study for patients with Neoplasms, Advanced Solid Tumors

UPDATED

Santa Monica California 90404

A Phase 1 clinical study for patients with Neoplasms, Advanced Solid Tumors

UPDATED

Santa Monica California 90404

A Phase 1 clinical study for patients with Neoplasms, Advanced Solid Tumors

UPDATED

Santa Monica California 90403

A Phase 1 clinical study for patients with Neoplasms, Advanced Solid Tumors

Colorado

NEW

Research Center
Additional Locations Colorado

Phase II/III Randomized study of Sorafenib plus Doxorubicin versus sorafenib in patients with advanced HCC

NEW

Research Center
Aurora Colorado

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

NEW

Research Center
Denver Colorado

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

Connecticut

NEW

Research Center
Additional Locations Connecticut

Phase II/III Randomized study of Sorafenib plus Doxorubicin versus sorafenib in patients with advanced HCC

NEW

Research Center
New Haven Connecticut

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

UPDATED

Farmington Connecticut 06030-2205

A Phase 1 clinical study for patients with Neoplasms, Advanced Solid Tumors

UPDATED

Farmington Connecticut 06030

A Phase 1 clinical study for patients with Neoplasms, Advanced Solid Tumors

Delaware

NEW

Research Center
Additional Locations Delaware

Phase II/III Randomized study of Sorafenib plus Doxorubicin versus sorafenib in patients with advanced HCC

NEW

Research Center
Newark Delaware

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

District of Columbia

NEW

Research Center
Additional Locations District of Columbia

A Phase III randomized, placebo-controlled, double-blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus Placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC)

NEW

Research Center
Additional Locations District of Columbia

Phase II/III Randomized study of Sorafenib plus Doxorubicin versus sorafenib in patients with advanced HCC

NEW

Research Center
District of Columbia District of Columbia

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

Florida

NEW

Research Center
Additional Locations Florida

A Phase III randomized, placebo-controlled, double-blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus Placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC)

NEW

Research Center
Additional Locations Florida

Phase II/III Randomized study of Sorafenib plus Doxorubicin versus sorafenib in patients with advanced HCC

NEW

Research Center
Gainesville Florida

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

NEW

Research Center
Miami Beach Florida

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

UPDATED

Tampa Florida 33612

A Phase 1 clinical study for patients with Neoplasms, Advanced Solid Tumors

Georgia

NEW

Research Center
Additional Locations Georgia

A Phase III randomized, placebo-controlled, double-blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus Placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC)

NEW

Research Center
Additional Locations Georgia

Phase II/III Randomized study of Sorafenib plus Doxorubicin versus sorafenib in patients with advanced HCC

UPDATED

Atlanta Georgia 30322

Patients are needed to participate in a clinical research study of ARQ 087 to evaluate Intrahepatic Cholangiocarcinoma or Combined Hepatocellular and Cholangiocarcinoma

Hawaii

NEW

Research Center
Additional Locations Hawaii

A Phase III randomized, placebo-controlled, double-blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus Placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC)

NEW

Research Center
Additional Locations Hawaii

Phase II/III Randomized study of Sorafenib plus Doxorubicin versus sorafenib in patients with advanced HCC

Idaho

NEW

Research Center
Additional Locations Idaho

Phase II/III Randomized study of Sorafenib plus Doxorubicin versus sorafenib in patients with advanced HCC

Illinois

NEW

Research Center
Additional Locations Illinois

A Phase III randomized, placebo-controlled, double-blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus Placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC)

NEW

Research Center
Additional Locations Illinois

Phase II/III Randomized study of Sorafenib plus Doxorubicin versus sorafenib in patients with advanced HCC

NEW

Research Center
Chicago Illinois

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

NEW

Research Center
Evanston Illinois

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

Indiana

NEW

Research Center
Additional Locations Indiana

Phase II/III Randomized study of Sorafenib plus Doxorubicin versus sorafenib in patients with advanced HCC

NEW

Research Center
Fort Wayne Indiana

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy